The FTC is requesting large, vertically-integrated players in the pharmacy benefit management industry share insights on their influence over drug pricing and access.
The request for information follows a previous public inquiry on PBMs, which revealed that independent pharmacies found contracts with PBMs to be confusing and predatory.
The request targets payers with vertically-integrated PBMs, including UnitedHealth Group's OptumRx, Cigna's Express Scripts and CVS Health's Caremark.
The public comment period extends through April 25.